What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

View Full Paper

Ask AI

Bookmark

Early identification of blast clearance improves complete remission rates, aiding personalized treatment.
Midostaurin and Gemtuzumab ozogamicin are utilized in standard treatment for acute myeloid leukemia.
Observational analysis across multiple centers evaluates the effectiveness of early blast assessment on treatment outcomes.
The approach may enable timely allogeneic HSCT allocation in high-risk patients with poor early response.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial shows improved CR rates in FLT3-mutated acute myeloid leukemia patients, indicating the significance of personalized treatment via blast clearance assessment.

Cite This Study

Audisio et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e02d https://doi.org/10.1182/blood-2025-5243

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows improved CR rates in FLT3-mutated acute myeloid leukemia patients, indicating the significance of personalized treatment via blast clearance assessment.

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Key Points

Discussion

Implication

Cite This Study

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading